Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone

Dexrazoxane has been reported to be protective against anthracycline induced subcutaneous ulceration in mice. It is currently under clinical investigation as an acute antidote in accidental anthracycline extravasation, for which indication topical dimethylsulfoxide (DMSO) and intralesional hydrocort...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2006, Vol.57 (1), p.125-128
Main Authors: LANGER, Seppo W, THOUGAARD, Annemette V, SEHESTED, Maxwell, JENSEN, Peter Buhl
Format: Article
Language:English
Subjects:
Administration, Topical
Animals
Antibiotics, Antineoplastic - adverse effects
Antineoplastic agents
Biological and medical sciences
Daunorubicin - adverse effects
Dimethyl Sulfoxide - administration & dosage
Dimethyl Sulfoxide - therapeutic use
Drug Therapy, Combination
Extravasation of Diagnostic and Therapeutic Materials - drug therapy
Extravasation of Diagnostic and Therapeutic Materials - etiology
Female
Hydrocortisone - administration & dosage
Hydrocortisone - therapeutic use
Injections, Intralesional
Injections, Intraperitoneal
Medical sciences
Mice
Mice, Inbred Strains
Pharmacology. Drug treatments
Razoxane - administration & dosage
Razoxane - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dexrazoxane has been reported to be protective against anthracycline induced subcutaneous ulceration in mice. It is currently under clinical investigation as an acute antidote in accidental anthracycline extravasation, for which indication topical dimethylsulfoxide (DMSO) and intralesional hydrocortisone are used empirically. We studied the effect in 72 mice of monotherapy with and combined therapy of intraperitoneal dexrazoxane, topical DMSO, and intralesional hydrocortisone as acute antidotes against ulceration after subcutaneous daunorubicin. Dexrazoxane completely prevented wounds from occurring, while neither DMSO nor hydrocortisone had any preventive effect. The addition of topical DMSO actually reduced the efficacy of dexrazoxane. In conclusion, the present study does not support the concomitant use of topical DMSO + systemic dexrazoxane or intralesional hydrocortisone + systemic dexrazoxane. Monotherapy with systemic dexrazoxane seems preferable and is highly efficacious in preventing ulceration.
ISSN:0344-5704
1432-0843
DOI:10.1007/s00280-005-0022-7